$1.66
6.74% day before yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

InflaRx N.V. Stock price

$1.66
+0.61 58.10% 1M
-0.08 4.60% 6M
-0.81 32.79% YTD
+0.21 14.48% 1Y
+0.27 19.42% 3Y
-5.83 77.84% 5Y
-13.33 88.93% 10Y
Nasdaq, Closing price Fri, May 16 2025
-0.12 6.74%
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

Key metrics

Market capitalization $111.44m
Enterprise Value $47.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 265.72
P/S ratio (TTM) P/S ratio 619.11
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth 178.84%
Revenue (TTM) Revenue $180.00k
EBIT (operating result TTM) EBIT $-61.24m
Free Cash Flow (TTM) Free Cash Flow $-51.68m
Cash position $71.14m
EPS (TTM) EPS $-1.05
P/E forward negative
P/S forward 264.55
EV/Sales forward 113.55
Short interest 1.78%
Show more

Is InflaRx N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

InflaRx N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a InflaRx N.V. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a InflaRx N.V. forecast:

Buy
88%
Hold
13%

Financial data from InflaRx N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.18 0.18
157% 157%
100%
- Direct Costs 1.03 1.03
14% 14%
572%
-0.84 -0.84
1% 1%
-467%
- Selling and Administrative Expenses 20 20
39% 39%
11,239%
- Research and Development Expense 40 40
10% 10%
22,011%
-61 -61
2% 2%
-33,717%
- Depreciation and Amortization 0.55 0.55
29% 29%
306%
EBIT (Operating Income) EBIT -61 -61
2% 2%
-34,025%
Net Profit -62 -62
66% 66%
-34,272%

In millions USD.

Don't miss a Thing! We will send you all news about InflaRx N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

InflaRx N.V. Stock News

Neutral
GlobeNewsWire
11 days ago
JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
18 days ago
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.
Neutral
GlobeNewsWire
about 2 months ago
JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025.
More InflaRx N.V. News

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Head office Netherlands
CEO Niels Riedemann
Employees 74
Founded 2007
Website www.inflarx.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today